Drug Profile
Research programme: nanobodies - Ablynx/Novo Nordisk
Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Ablynx
- Developer Ablynx; Novo Nordisk
- Class Antibodies; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for research development in Unspecified in Belgium (Parenteral)
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 25 Nov 2015 Early research in Undefined indication in Belgium (Parenteral)